Searched for
CIPLA CHINA PLANT
Jubilant Ingrevia from India joins WEF's Global Lighthouse NetworkJubilant Ingrevia's Gujarat facility joins the World Economic Forum's Global Lighthouse Network, emphasizing its role in AI-driven manufact...- Cipla expects to commence supplies to US from China plant later this yearCipla plans to start supplying from its China facility to the US market by the second half of the current fiscal year, following USFDA appr...
- Cipla eyes acquisitions after Covid windfallFounded in 1935 by Hamied’s grandfather in then-colonial Bombay, Cipla made its name globally by pioneering the sale of cheap, generic HIV ...
- For US-facing pharma cos, Q2 & Q3 likely to be soft quarters: Nithya Balasubramanian“For the next couple of quarters, on a YoY basis, I am expecting that generic price deflation could be higher in the second as well as the ...
- Covid spike fails to spook India Inc as operations with limited workforce continueSome companies like Coca-Cola India, Dabur, Maruti, Cipla, Whirlpool and MakeMyTrip have opened some of their offices, plants and labs. Non...
- Q4 earning preview: Pharma pack up for good show, may go unscathed from virus hitInvestors may keenly follow Sun Pharma earnings for updates on Halol OAI.
- Top ibuprofen maker rallies as China lockdown disrupts supply“There will be a supply gap and we expect to benefit,” Garg said in a telephone interview.
- Four Cs to determine the course for Indian pharmaA review of FY19 points to four dominant themes that hold the future for India's pharma industry.
- Cipla is undergoing a big transformation and is doing something it once eschewedA difficult transformation is underway at Cipla, one of India’s largest and oldest pharma companies.
- Buy Cipla, target Rs 720: SharekhanBuy Cipla Ltd. at a price target of Rs 720.
- Hamsons buys 21% stake in Okasa PharmceuticalsWhile Cipla paid Rs 29 crore for Okasa’s facility in Goa, it bought another plant, owned by Okasa Pharma, located in Satara for Rs 71.93 cr...
- Twelve stocks in focus in Tuesday morning tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to be in focus today.
- Market valuation far exceeds estimates, correction due soon: Bhavin Shah, Equirus Securities"However, the market is perhaps trying to price in a much stronger economic recovery, which does not seem that unlikely anymore."
- India-China CEOs forum aims to give boost to bilateral tradeCorporate leaders from India are slated to establish channels for dialogue with their Chinese counterparts.
- PM clears Anil Ambani's name to lead India-China CEOs forumIndustrialist Anil Ambani will lead the Indian side of the India-China CEOs forum, which would focus on boosting the economic and commercia...
- Ranbaxy to step up head count, launch new drugsRanbaxy Laboratories, hit by charges of sub-standard drugs, is raising sales staff by a third and launching scores of new drugs that would ...
- Cipla plans to raise Rs 1,500 cr to retire debt, fund capexCipla plans to raise Rs 1,500 crore either by issuing foreign currency convertible bonds or through global depository receipts to clear its...
- NPPA cuts prices of three bulk drugs; Cipla, GSK to take a hitNPPA has reduced the price of salbutamol sulphate by almost 6% to Rs 4,478 per kg from Rs 4,748 per kg.
- India, China drug makers to cut malaria drug price: ClintonFormer US president Bill Clinton has announced a deal with six pharmaceutical companies from China and India to cut the price of a leading ...
- Indian pharmas increase API imports from ChinaEven as Indian active pharmaceutical ingredients (API) makers compete with Chinese companies globally, growing API imports from China to In...
Load More
